1.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: Over 60
Sponsor: Other
Protocol IDs: AML-elderly 01/99 Trial, NCT00199147
|
|
2.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 0 to 75
Sponsor: Other
Protocol IDs: LPA 2005, NCT00408278
|
|
3.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 60
Sponsor: Other
Protocol IDs: TPH/SCU-IMed 01/08, NCT00838019
|
|
4.
|
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: Other
Protocol IDs: PETHEMA-LAM07, NCT01041040
|
|
5.
|
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: Other
Protocol IDs: UHW-AML16, EU-20677, ISRCTN11036523, EUDRACT-2005-002846-14, MREC-CU106, NCT00454480
|
|
6.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: IAPLSG2004, BT/PR4460/Med/14/531/2003, NCT00517712
|
|
7.
|
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: MYFLAI07, NCT00909168
|
|
8.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 16 and over
Sponsor: Other
Protocol IDs: AMLCG 99, BMBF 01 GI 02070, NCT00266136
|
|
9.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Under 30
Sponsor: NCI
Protocol IDs: COG-AAML0531, AAML0531, NCT00372593
|
|
10.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: P050604, NCT00378365
|
|
11.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 60
Sponsor: Other
Protocol IDs: P060504, EudraCT N° : 2006-005163-26, NCT00428558
|
|
12.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: GIMEMA-DSL-APL0406, EUDRACT-2006-006188-22, APL0406, EU-20725, NCT00482833
|
|
13.
|
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: SWOG-S0521, S0521, NCT00492856
|
|
14.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 16 to 65
Sponsor: Other
Protocol IDs: NILG-AML 02/06, NCT00495287
|
|
15.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 59
Sponsor: NCI
Protocol IDs: CALGB-10603, CALGB 10603, EUDRACT-2006-006852-37, NCT00651261
|
|
16.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 60 and over
Sponsor: Other
Protocol IDs: CHUBX 2007/13, NCT00590837
|
|
17.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 60
Sponsor: Other
Protocol IDs: BRD 06/10-I, NCT00860639
|
|
18.
|
Phase: Phase III
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: AMLSG 09-09, NCT00893399
|
|
19.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 50 to 70
Sponsor: Other
Protocol IDs: ALFA 0701, NCT00927498
|
|
20.
|
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 60 and over
Sponsor: NCI
Protocol IDs: ECOG-E2906, E2906, NCT01041703
|
|
21.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: S-WHITE-22304, 50047, S-WHITE-050047, NCT00397579
|
|
22.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NYCC-6898, 6898, NCI-6898, NCT00392353
|
|
23.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 12 to 75
Sponsor: Other
Protocol IDs: CIK#1/2006, NCT00394381
|
|
24.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 60 and over
Sponsor: Other
Protocol IDs: CAN-NCIC-IND186, IND186, NCT00516828
|
|
25.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: AT9283/0002, 2006-0177, NCT00522990
|
